Pharmacophore modelling and atom-based 3D-QSAR studies on N-methyl pyrimidones as HIV-1 integrase inhibitors

Pharmacophore modelling and atom-based 3D-QSAR studies were carried out for a series of compounds belonging to N-methyl pyrimidones as HIV-1 integrase inhibitors. Based on the ligand-based pharmacophore model, we got 5-point pharmacophore model AADDR, with two hydrogen bond acceptors (A), two hydrogen bond donors (D) and one aromatic ring (R). The generated pharmacophore-based alignment was used to derive a predictive atom-based 3D-QSAR model for the training set (r2 = 0.92, SD = 0.16, F = 84.8, N = 40) and for test set (Q2 = 0.71, RMSE = 0.06, Pearson R = 0.90, N = 10). From these results, AADDR pharmacophore feature was selected as best common pharmacophore hypothesis, and atom-based 3D-QSAR results also support the outcome by means of favourable and unfavourable regions of hydrophobic and electron-withdrawing groups for the most potent compound 30. These results can be useful for further design of new and potent HIV-1 IN inhibitors.

[1]  G. Cohen,et al.  Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Engelman,et al.  Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro , 1992, Journal of virology.

[3]  David E. Shaw,et al.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..

[4]  J. Mouscadet,et al.  HIV-1 integrase: the next target for AIDS therapy? , 2001, Pathologie-biologie.

[5]  Heather Donaghy,et al.  Manipulation of dendritic cell function by viruses. , 2010, Current opinion in microbiology.

[6]  W. Powderly.  Integrase inhibitors in the treatment of HIV-1 infection. , 2010, The Journal of antimicrobial chemotherapy.

[7]  P. Brown,et al.  Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. , 1992, Science.

[8]  T. Halgren.  MMFF VI. MMFF94s option for energy minimization studies , 1999, J. Comput. Chem..

[9]  A. Gronenborn,et al.  Solution structure of the N-terminal zinc binding domain of HIV-1 integrase , 1997, Nature Structural Biology.

[10]  M. Degani,et al.  Pharmacophore Refinement and 3D-QSAR Studies of Histamine H3 Antagonists , 2007 .

[11]  F. Bushman,et al.  Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Hagmann.  Study confirms effectiveness of antiretroviral drugs for HIV patients. , 2003, Bulletin of the World Health Organization.

[13]  N. Tawari,et al.  Pharmacophore mapping of a series of pyrrolopyrimidines, indolopyrimidines and their congeners as multidrug-resistance-associated protein (MRP1) modulators , 2008, Journal of molecular modeling.

[14]  D. Grandgenett,et al.  Concerted integration of retrovirus-like DNA by human immunodeficiency virus type 1 integrase , 1995, Journal of virology.

[15]  Ya-wen Wang,et al.  Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110α inhibitors , 2010, Journal of molecular modeling.

[16]  Thomas A. Halgren.  MMFF VI. MMFF94s option for energy minimization studies , 1999, J. Comput. Chem..

[17]  M. Gottlieb,et al.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. , 1981, The New England journal of medicine.

[18]  Michael Rowley,et al.  Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones. , 2007, Journal of medicinal chemistry.

[19]  D. Hazuda,et al.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.

[20]  Robert Craigie,et al.  HIV Integrase, a Brief Overview from Chemistry to Therapeutics* , 2001, The Journal of Biological Chemistry.

[21]  David A. Evans,et al.  3D QSAR Methods: Phase and Catalyst Compared , 2007, J. Chem. Inf. Model..

[22]  G. Kukolj,et al.  Enhanced and coordinated processing of synapsed viral DNA ends by retroviral integrases in vitro. , 1995, Genes & development.

[23]  Alexander Tropsha,et al.  Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.

[24]  A. Engelman,et al.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. , 1994, Science.

[25]  Steven L Dixon,et al.  PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching , 2006, Chemical biology & drug design.

[26]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[27]  D J Morris,et al.  Does HIV cause AIDS? , 1990, Journal of acquired immune deficiency syndromes.

[28]  Carlo A. Furia,et al.  User manual , 2023, International Transport Forum Policy Papers.

[29]  H. Masur,et al.  An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. , 1981, The New England journal of medicine.